Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

COVID-19: Omicron may not evade all monoclonal antibodies, says study - BusinessToday

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic - ScienceDirect

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic - ScienceDirect

Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants - eBioMedicine

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

The scientific race to understand the Omicron variant

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies - eBioMedicine

Covid antibody treatments that don't work against omicron still being used in some states.

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages - ScienceDirect

Why the Omicron BA.5 Variant Evades Vaccines

Op-Ed: Could the COVID-19 virus mutate to evade the vaccines? - Los Angeles Times